A Phase 4 interventional study of Tegoprazan 50mg QD and Lansoprazole 30mg QD in Erosive Reflux Disease, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-07-29.
Sponsored by HK inno.N Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to evaluate the efficacy and safety of Tegoprazan 50mg, compared to Lansoprazole 30mg in patients with healed erosive reflux disease confirmed by endoscopy following oral administration once daily(QD) of 2 weeks or 4 weeks.
This is a double blind, radomized, active-controlled, phase 4 study. Subjects will be randomly assigned to one of the two treatment groups (Tegoprazan 50mg, Lansoprazole 30mg)
HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Tegoprazan 50mg tablet, once daily, oral administration
Drug: Tegoprazan 50mg QD
Lansoprazole 30mg capsule, once dauly, oral administration
Drug: Lansoprazole 30mg QD
Tegoprazan 50mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
Lansoprazole 30mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
4 weeks cumulative ERD healing rate(%)
Healing is defined as "not present" erosions or fissures according to the LA classification.
Time frame: 4 weeks
2 weeks ERD healing rate(%)
Healing is defined as "not present" erosions or fissures according to the LA classification.
Time frame: 2 weeks
Healing rate(%) at 2 weeks and 4 weeks according to CYP2C19 genotype type
Extensive Metaboliser (EM), Intermediate Metaboliser (IM), Poor Metaboliser (PM)
Time frame: 2 weeks or 4 weeks
Percentage of days without heartburn through the clinical trial subject dairy (%)
On days with no symptoms of heartburn, '0. It is defined as a case assessed as having no symptoms.
Time frame: 2 weeks or 4 weeks
RDQ (Reflux Disease Questionnaire) evaluation(mean change in severity)
Average scale change in RDQ severity and frequency at 2 weeks and 4 weeks after administration compared to before administration of investigational drugs for each category (heartburn, indigestion, acid reflux)
Time frame: 2 weeks or 4 weeks
Incidence of Adverse Events [Safety]
Physical examination(weight-kg)(height-cm), vital signs(SBP, DBP, heart rate, body temperature), adverse reactions, blood chemistry test
Time frame: 2 weeks or 4 weeks
Ran from Feb 2021 to primary completion in May 2022, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tegoprazan